Eric Karas
CIK: 0001951287
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
ARS Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (16 total)
- Jun 12, 2026SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct25K shares at avg. $1.50$38K - Jun 12, 2026SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct25K shares at avg. $10.00$250K - Jan 2, 2026SPRY
ARS Pharmaceuticals, Inc.
Award(A)DirectStock option (right to buy)
240K shares- - Jul 1, 2025SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct15K shares at avg. $16.99$255K - Jul 1, 2025SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct15K shares at avg. $1.50$23K - Jun 18, 2025SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct15K shares at avg. $1.50$23K - Jun 18, 2025SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct15K shares at avg. $16.00$240K - Mar 20, 2025SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct10K shares at avg. $14.00$140K - Mar 20, 2025SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct10K shares at avg. $1.50$15K - Jan 2, 2025SPRY
ARS Pharmaceuticals, Inc.
Award(A)DirectStock option (right to buy)
152.3K shares- - Dec 4, 2024SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct6.3K shares at avg. $1.50$9K - Dec 4, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct6.3K shares at avg. $14.00$88K - Dec 2, 2024SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct3.7K shares at avg. $1.50$6K - Dec 2, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct3.7K shares at avg. $14.11$52K - Sep 18, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct10K shares at avg. $14.00$140K - Sep 18, 2024SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct10K shares at avg. $1.50$15K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 12, 2026 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 25,000 | $1.50 | $37,500 | Direct |
| Jun 12, 2026 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 25,000 | $10.00 | $250,000 | Direct |
| Jan 2, 2026 | SPRY ARS Pharmaceuticals, Inc. | Award(A) Stock option (right to buy) | 240,000 | - | - | Direct |
| Jul 1, 2025 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 15,000 | $16.99 | $254,861 | Direct |
| Jul 1, 2025 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 15,000 | $1.50 | $22,500 | Direct |
| Jun 18, 2025 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 15,000 | $1.50 | $22,500 | Direct |
| Jun 18, 2025 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 15,000 | $16.00 | $240,000 | Direct |
| Mar 20, 2025 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 10,000 | $14.00 | $140,000 | Direct |
| Mar 20, 2025 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 10,000 | $1.50 | $15,000 | Direct |
| Jan 2, 2025 | SPRY ARS Pharmaceuticals, Inc. | Award(A) Stock option (right to buy) | 152,300 | - | - | Direct |
| Dec 4, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 6,283 | $1.50 | $9,425 | Direct |
| Dec 4, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 6,283 | $14.00 | $87,962 | Direct |
| Dec 2, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 3,717 | $1.50 | $5,576 | Direct |
| Dec 2, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 3,717 | $14.11 | $52,461 | Direct |
| Sep 18, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 10,000 | $14.00 | $140,000 | Direct |
| Sep 18, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 10,000 | $1.50 | $15,000 | Direct |
1-16 of 16 transactions
About Karas Eric
Karas Eric (SEC CIK 0001951287) files insider reports with the SEC as Chief Commercial Officer of ARS Pharmaceuticals, Inc. (SPRY).
Signal8 holds 8 ownership filings by Karas Eric, all Form 4s, filed between Sep 19, 2024 and Jun 12, 2026. Those filings report 16 transactions, from Sep 18, 2024 to Jun 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Karas Eric's filings is in SAN DIEGO, CA.
Recent filings by Karas Eric
- Jun 12, 2026: Option exercise of SPRY shares (Form 4, code M).
- Jun 12, 2026: Open-market sale of SPRY shares (Form 4, code S).
- Jan 2, 2026: Grant or award of SPRY derivative securities (Form 4, code A).
- Jul 1, 2025: Open-market sale of SPRY shares (Form 4, code S).
- Jul 1, 2025: Option exercise of SPRY shares (Form 4, code M).
Other insiders filing for ARS Pharmaceuticals, Inc. (SPRY)
- Casale Donn, President and CEO
- Smith Margaret Ekins, Chief Commercial Officer
- RA CAPITAL MANAGEMENT, L.P., Director
- Dadoo Rajeev, Director
- Shah Pratik, Director
- Kelly Michael, Director